<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="241">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04375202</url>
  </required_header>
  <id_info>
    <org_study_id>2020-001475-33</org_study_id>
    <nct_id>NCT04375202</nct_id>
  </id_info>
  <brief_title>Colchicine in COVID-19: a Pilot Study</brief_title>
  <acronym>COLVID-19</acronym>
  <official_title>Treatment With COLchicine of Patients Affected by COVID-19: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Of Perugia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional, pilot, multicenter, randomized, open-label, phase 2 study,
      enrolling patients with COVID-19 disease. One-month rate of entering the critical stage
      (either a. Respiratory failure occurs and requires mechanical ventilation; b. Patients
      combined with other organ failure need ICU monitoring and treatment; c. Death) is the primary
      endpoint.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, pilot, multicenter, randomized, open-label, phase 2 study,
      enrolling patients with COVID-19 disease. Participants will be randomized in a 1:1 ratio to
      receive Colchicine plus current care versus current care.

      One-month rate of entering the critical stage (either a. Respiratory failure occurs and
      requires mechanical ventilation; b. Patients combined with other organ failure need ICU
      monitoring and treatment; c. Death) is the primary endpoint. Secondary objectives are trend
      of White blood cell count, Change of the &quot;Sequential Organ failure Assessment&quot; (SOFA), Rate
      of biochemical criterion (CK, ALT,ferritin) recovery, Rate of disease remission and safety of
      Colchicine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of entering the critical stage</measure>
    <time_frame>[1 month]</time_frame>
    <description>Comply with any of the followings:
Respiratory failure occurs and requires mechanical ventilation;
Patients combined with other organ failure need ICU monitoring and treatment
Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trend of White blood cell count</measure>
    <time_frame>[up to 30 days]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the &quot;Sequential Organ failure Assessment&quot; (SOFA)</measure>
    <time_frame>[up to 30 days]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of biochemical criterion (CK, ALT, ferritin) recovery</measure>
    <time_frame>[up to 30 days]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of disease remission</measure>
    <time_frame>[up to 30 days]</time_frame>
    <description>Comply with any of the followings:
No fever, cough and other symptoms;
SPO2&gt;94% or PaO2/FiO2 &gt;350mmHg without oxygen inhalation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of Colchicine</measure>
    <time_frame>[up to 30 days]</time_frame>
    <description>Rate of adverse events codified by Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Colchicine plus current care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine 0.5 mg three times a day if weight is less than 100 kg; 1 mg twice a day if weight is more than 100 kg for 30 days or up to discharge. Reduce based on gastrointestinal symptoms appearance at discretion of the Investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Current care alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Current care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine 1 MG Oral Tablet</intervention_name>
    <description>Tablets for oral administration, containing 1 mg of the active ingredient colchicine, administered 0.5 mg po every 8 hours x 30 days.</description>
    <arm_group_label>Colchicine plus current care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent for participation in the study

          -  Virological diagnosis of SARS-CoV-2 infection (real-time PCR)

          -  Hospitalized due to clinical/instrumental diagnosis of pneumonia

          -  Oxygen saturation at rest in ambient air ≤94%

          -  PaO2/FiO2 ratio of 350 to 200

        Exclusion Criteria:

          -  Known hypersensitivity to colchicine or its excipients

          -  Severe diarrhea

          -  Patients who cannot take oral therapy

          -  Pregnant and lactating patients

          -  Patients with severe cardiac, renal insufficiency (creatinine clearance (CCL) &lt;30 mL /
             min)

          -  Patients with kidney or liver damage [(AST or ALT&gt; 5 times the normal limits in
             International Units (ULN)]; or are taking CYP3A4 enzyme - P glycoprotein inhibitors.

          -  Known other clinical condition that contraindicates colchicine and cannot be treated
             or solved according to the judgement of the clinician

          -  Neutrophils &lt;1.000 / mmc

          -  Platelets &lt;50.000 / mmc

          -  Bowel diverticulitis or perforation

          -  Patients already in ICU or requiring mechanical ventilation

          -  Patients receiving Tocilizumab

          -  Patients already enrolled in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Associazione Italiana Pneumologi Ospedalieri</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Diana</last_name>
      <phone>+39 0236590350</phone>
      <email>aipocentrostudi@aiporicerche.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Società Italiana di Reumatologia</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Scirè</last_name>
      <phone>+390265560677</phone>
      <email>centrostudisir@reumatologia.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://www.aifa.gov.it/sperimentazioni-cliniche-covid-19</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, Perricone R, Gerli R. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 Jul;111:102468. doi: 10.1016/j.jaut.2020.102468. Epub 2020 Apr 17. Review.</citation>
    <PMID>32317220</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>May 3, 2020</last_update_submitted>
  <last_update_submitted_qc>May 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Of Perugia</investigator_affiliation>
    <investigator_full_name>Prof Roberto Gerli</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>COVID</keyword>
  <keyword>COVID-19</keyword>
  <keyword>CORONAVIRUS</keyword>
  <keyword>SARS-COV-2</keyword>
  <keyword>COLCHICINE</keyword>
  <keyword>IL-1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

